Inke’s Near-Term Emissions Reduction Targets Approved by the SBTi

Inke is proud to announce that its near-term emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi). This milestone represents a key step in our ongoing commitment to sustainability and climate action.

As part of our comprehensive ESG strategy, Inke has set ambitious goals to reduce its Scope 1 and 2 greenhouse gas (GHG) emissions by 42% by 2030, using 2023 as the base year. These targets align with the global 1.5°C climate goal and are designed to address the most pressing environmental challenges of our time.

In addition, we are actively working to reduce our Scope 3 emissions, focusing on areas such as purchased goods, business travel, and employee commuting. Inke’s commitment to reducing emissions goes beyond regulatory compliance—it’s about ensuring a positive environmental impact and contributing to the global fight against climate change.

This validation from the SBTi reinforces our dedication to achieving measurable, science-backed climate goals. We are excited to continue leading by example in the pharmaceutical industry, working towards a more sustainable future for all.

Stay tuned for future updates on our progress and the steps we are taking to achieve these ambitious targets.